Half Year Result 20171

CSL Delivers Exceptional Performance

Melbourne, Australia — 15/02/2017

Global biotechnology leader CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of $806 million for the six months ended 31 December 2016, up $87 million or 12% on a reported basis when compared to the prior comparable period (PCP). Reported earnings per share (EPS) grew 14%. Underlying2 NPAT grew 36% and earnings per share (EPS) increased 39% on a constant currency (CC)3 basis, after excluding the one-off items related to the Novartis influenza vaccines business acquisition during the previous period.

Half Year Results Announcement 2017



  • Revenue $3,677 million
    • Up 18% at CC
  • Earnings before interest and tax (EBIT) $1,095 million
    • Underlying EBIT up 38% at CC
  • NPAT $806 million
    • Underlying NPAT up 36% at CC
  • EPS $1.77
    • Reported EPS up 14%
    • Underlying EPS up 39% at CC
  • Interim dividend4 increased to $0.64 per share

1 All figures are expressed in US dollars unless otherwise stated. 2 Underlying excludes from 1H16 financials the one off items relating to the Novartis influenza vaccines business (NVS-IV), which was acquired on 31 July 2015. 3 Constant currency removes the impact of exchange rate movements to facilitate comparability. See end note for further detail. 4 For shareholders with an Australian registered address, dividends will be unfranked for Australian tax purposes and paid on 13 April 2017 in A$ at an amount of A$0.837760 per share (at an exchange rate of A$1.3090/US$1.00). For shareholders with a New Zealand registered address, dividends will be paid in NZD at an amount of NZ$0.892160 per share (at an exchange rate of NZ$1.3940/US$1.00). The exchange rates used are fixed at the date of dividend determination. All other shareholders will be paid in US$. CSL also offers shareholders the opportunity to receive dividend payments in US$ by direct credit to a US bank account.

Download This Release

Additional resources:
Details about CSL's results are included in the company's 4D statement, investor presentation slides and webcast. More ...

For further information, please contact:

  Mark Dehring
  Head of Investor Relations
  CSL Limited
  Phone: +613 9389 3407
  Email: mark.dehring@csl.com.au
  Jemimah Pentland
  Head of Asia Pacific Communications
  CSL Limited
  Phone: +613 9389 3473
  Mobile: +61 412 635 483
  Email: Jemimah.Pentland@csl.com.au

© 2017 CSL Limited